Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Developing Neuronal KCNQ Channel Modulators for Mood Disorders

Trial Profile

Developing Neuronal KCNQ Channel Modulators for Mood Disorders

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Retigabine (Primary)
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 03 Mar 2021 Primary endpoint (Change in the cortico-striatal circuit response) has not been met, as per Results published in the American Journal of Psychiatry
    • 03 Mar 2021 Results published in the American Journal of Psychiatry
    • 06 Sep 2019 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top